The Bill will remove the cap of $5,000 from the NJRR Levy Act that can be imposed per medical device listed on the Prescribed List of Medical Devices and Human Tissue products for a financial year. With this change the levy will be allocated in proportion to the actual volume of devices supplied by medical device companies creating a fairer and more equitable distribution of the levy.By removing the flat cap, the government intends to shift the burden of cost recovery so that it is proportional to the market presence and volume of devices supplied by each company. This ensures that high-volume suppliers contribute a share of the registry's costs that reflects their usage and impact on the system, rather than benefiting from a ceiling that disproportionately advantages large-scale operations over smaller competitors. The amendment is scheduled to apply to the financial year beginning 1 July 2027 and subsequent years. [Explanatory Memo page 1]
The primary justification for this bill is the pursuit of horizontal equity within the medical device industry. Under the current system, the $5,000 cap creates a regressive levy structure where high-volume manufacturers pay a significantly lower effective rate per unit compared to smaller competitors. By removing this arbitrary ceiling, the bill ensures that the costs of the National Joint Replacement Registry (NJRR) are distributed in direct proportion to the volume of devices a company places on the market.
From a utilitarian perspective, this amendment strengthens the "user-pays" cost-recovery model that sustains the NJRR. The registry provides a vital public good by monitoring the safety and efficacy of joint replacements, which benefits manufacturers by maintaining public confidence in their products. It is only logical that those who derive the greatest commercial benefit from the market—and who contribute the most data points to the registry—should bear a proportionate share of its administrative costs [Judgment]. This ensures the long-term financial viability of a critical health safety mechanism without placing an undue burden on the Commonwealth's general revenue.
The removal of the $5,000 cap introduces a level of financial unpredictability for medical device companies that may have negative downstream effects on the Australian healthcare system. While the government frames this as an "equitable" change, it essentially removes a known cost ceiling, potentially leading to significant cost increases for high-volume, low-margin essential devices. There is a significant risk that these increased regulatory costs will simply be passed on to private health insurers, ultimately resulting in higher premiums for consumers.[1]
Furthermore, the bill assumes that "volume" is the only relevant metric for fairness. However, a flat proportional levy fails to account for the varying levels of complexity and risk associated with different devices. A high-volume, simple component might now be taxed more heavily than a low-volume, highly complex prosthesis that requires far more intensive monitoring by the registry. Without a cap, the levy risks becoming a punitive tax on market success rather than a calibrated cost-recovery mechanism [Judgment].
Increased levies on medical devices are frequently cited by industry bodies as a driver for rising private health insurance costs.
2026-09-17
House of Representatives
Before House of Representatives
Unspecified
Health, Disability and Ageing
Healthcare, Financial Regulation, Competition Policy